Methods and compositions for genetic modulation
Described herein are methods for modulating expression of a gene in a cell by contacting the cell with a gene modulation composition, such as a composition including an electrolyzed saline solution.
1. A method of modulating expression of a gene in a cell comprising contacting the cell with a composition comprising an electrolyzed saline solution, the electrolyzed saline solution comprising a mixture of reduced species and reactive species, thereby modulating expression of the gene, wherein the electrolyzed saline solution comprises HOCl −1 , OCl −1 , Cl −1 , Cl 2 , O 2 3 , O 3 , and H 2 O 2 .
2. The method of claim 1 , wherein the cell is an isolated cell.
3. The method of claim 1 , wherein the modulating expression of the gene comprises changing expression of the gene, and wherein the method further comprises detecting the change in expression of the gene.
4. The method of claim 3 , wherein the cell is located in situ in a subject, and wherein detecting comprises inferring a change in the expression of the gene from a physiological change in the subject.
5. The method of claim 3 , wherein detecting comprises performing one or more of ELISA, immunohistochemistry, Northern blot, Southern blot, or PCR.
6. The method of claim 1 , wherein the cell is located in situ in a subject, and wherein contacting comprises administering to the subject an amount of the composition effective to modulate expression of the gene.
7. The method of claim 6 , wherein the subject is human.
8. The method of claim 6 , wherein the composition is administered orally.
9. The method of claim 6 , wherein the composition is administered in an amount of about 0.1 ounce to about 12 ounces at a frequency of four times daily to one time monthly for a period of one day to 10 years.
10. The method of claim 1 , wherein the gene encodes C-C chemokine receptor type 10 (CCR10), coiled-coil domain-containing protein 126 (CCDC126), DnaJ homolog subfamily C member 3 (DNAJC3), early growth response protein 1 (EGR1), embigin (EMB), immunoglobulin lambda variable 1-41 (IGLV1-41), immunoglobulin lambda variable 1-51 (IGLV1-51), interleukin-1 receptor-associated kinase 3 (IRAK3), potassium channel tetramerization domain containing 12 (KCTD12), pyridine nucleotide-disulfide oxidoreductase domain 1 (PYROXD1), or WD repeat-containing protein 11 (WDR11).
11. The method of claim 1 , wherein the composition has a pH between about 6 and about 9.
12. The method of claim 1 , wherein the composition comprises a solution containing 1000 ppm to 1400 ppm sodium, 1200 ppm to 1600 ppm chloride, 16 ppm to 24 ppm hypochlorous acid, at least 94 μM superoxide radical, and at least 241 μM hydroxyl radical.
13. The method of claim 1 , wherein the one or more reactive species comprises one or more of active chlorine species in an amount of about 5 to about 300 ppm, active oxygen species in an amount of about 0.1 to about 300 ppm, or active hydrogen species in an amount of about 5 to about 300 ppm.
14. The method of claim 13 , wherein the active chlorine species comprises at least one of an active chlorine species selected from the group consisting of: free chlorine, hypochlorous acid and hypochlorite ion.
15. The method of claim 14 , wherein the electrolyzed saline solution is prepared using a saline solution with a starting sodium chloride solution selected from the group consisting of: 0.9% NaCl (w/vol), 0.45% NaCl (w/vol), and 0.215% NaCl (wt/vol).
16. The method of claim 1 , wherein the electrolyzed saline solution is prepared by subjecting a saline solution comprising sodium chloride in an amount of about 0.05 to about 10% to electrolysis under conditions sufficient to produce the one or more reactive species.
17. The method of claim 1 , wherein expression of the gene is modulated by greater than 2 fold change compared to expression of the gene in an untreated cell.
18. The method of claim 1 , wherein gene expression is increased in CCDC126, CCR10, EGR1, IGLV1-41, or IGLV1-51.
19. The method of claim 1 , wherein gene expression is decreased in DNAJC3, EMB, IRAK3, KCTD12, PYROXD1, or WDR11.
20. A method of modulating expression of a gene in a cell comprising contacting the cell with a composition comprising an electrolyzed saline solution, the electrolyzed saline solution comprising a mixture of reduced species and reactive species, thereby modulating expression of the gene, wherein the composition comprises a solution containing 1000 ppm to 1400 ppm sodium, 1200 ppm to 1600 ppm chloride, 16 ppm to 24 ppm hypochlorous acid, at least 94 μM superoxide radical, and at least 241 μM hydroxyl radical.
21. The method of claim 20 , wherein the modulating expression of the gene comprises changing expression of the gene, and wherein the method further comprises detecting the change in expression of the gene.
22. The method of claim 20 , wherein the cell is located in situ in a subject, and wherein contacting comprises administering to the subject an amount of the composition effective to modulate expression of the gene.
23. The method of claim 20 , wherein the gene encodes C-C chemokine receptor type 10 (CCR10), coiled-coil domain-containing protein 126 (CCDC126), DnaJ homolog subfamily C member 3 (DNAJC3), early growth response protein 1 (EGR1), embigin (EMB), immunoglobulin lambda variable 1-41 (IGLV1-41), immunoglobulin lambda variable 1-51 (IGLV1-51), interleukin-1 receptor-associated kinase 3 (IRAK3), potassium channel tetramerization domain containing 12 (KCTD12), pyridine nucleotide-disulfide oxidoreductase domain 1 (PYROXD1), or WD repeat-containing protein 11 (WDR11).
24. The method of claim 20 , wherein the electrolyzed saline solution is prepared by subjecting a saline solution comprising sodium chloride in an amount of about 0.05 to about 10% to electrolysis under conditions sufficient to produce the one or more reactive species.